Table 1.
Patient characteristics at the time of cfDNA collection in the test and validation cohorts of men with mCRPC.
| Test Cohort | Validation Cohort | |||
|---|---|---|---|---|
| NEPC N = 9 | PRAD N = 39 | NEPC N = 12 | PRAD N = 41 | |
| Median cfDNA Tumor Content (Range) | 15% (5.1-75%) | 21% (3.3-80%) | 23% (3.4-43%) | 16% (3.8-49%) |
| Median Age (Range) | 72 (60-84) | 71 (61-92) | 71 (54-91) | 70 (49-86) |
| Median PSA (Range) | 0.37 (0.03-3.7) | 140 (0.79-4305) | 0.33 (0.01-6.23) | 112 (4.5-1821) |
| De Novo NEPC | 3 (33%) | N/A | 2 (17%) | N/A |
| Prior Local Therapy | 5 (56%) | 27 (69%) | 5 (42%) | 26 (63%) |
| Prior ADT | 4 (44%) | 39 (100%) | 8 (67%) | 41 (100%) |
| Prior Abiraterone or Enzalutamide | 0 (0%) | 36 (92%) | 4 (33%) | 39 (95%) |
| Prior Docetaxel | 2 (22%) | 25 (64%) | 2 (17%) | 35 (85%) |
| Prior EP Chemotherapy | 7 (78%) | 0 (0%) | 8 (67%) | 0 (0%) |
| Liver Metastases | 3 (33%) | 15 (38%) | 8 (67%) | 13 (32%) |
Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; cfDNA, cell-free DNA; NEPC, neuroendocrine prostate cancer; PRAD, prostate adenocarcinoma; PSA, prostate-specific antigen; N/A, not applicable; ADT, androgen deprivation therapy; ARSI, androgen receptor signaling inhibitor; EP, etoposide plus platinum.